Cargando…

A Comparison of Treatment Effect Sizes in Matched Phase 2 and Phase 3 Trials of Advanced Therapeutics in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis

INTRODUCTION: Phase 2 trials are fundamental to the rational and efficient design of phase 3 trials. We aimed to determine the relationship of treatment effect size estimates from phase 2 and phase 3 clinical trials on advanced therapeutics in inflammatory bowel disease. METHODS: MEDLINE, EMBASE, CE...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hanzel, Jurij, Solitano, Virginia, Zou, Lily, Zou, G.Y., Peyrin-Biroulet, Laurent, Danese, Silvio, Singh, Siddharth, Ma, Christopher, Wils, Pauline, Jairath, Vipul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer 2023
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684248/ https://www.ncbi.nlm.nih.gov/pubmed/37578211 http://dx.doi.org/10.14309/ctg.0000000000000629

Ejemplares similares

Comparison of treatment effect between phase 2 and phase 3 trials in patients with inflammatory bowel disease
por: Wils, Pauline, et al.
Publicado: (2023)

The European Perspective and History on Biosimilars for the Treatment of Inflammatory Bowel Diseases
por: Solitano, Virginia, et al.
Publicado: (2021)

Abdominal Pain in Inflammatory Bowel Diseases: A Clinical Challenge
por: Wils, Pauline, et al.
Publicado: (2022)

Early Intervention in Ulcerative Colitis: Ready for Prime Time?
por: Solitano, Virginia, et al.
Publicado: (2020)

Evolution of IL-23 Blockade in Inflammatory Bowel Disease
por: Danese, Silvio, et al.
Publicado: (2022)

Key Strategies to Optimize Outcomes in Mild-to-Moderate Ulcerative Colitis
por: Solitano, Virginia, et al.
Publicado: (2020)

Selective Tyrosine Kinase 2 Inhibition for Treatment of Inflammatory Bowel Disease: New Hope on the Rise
por: Danese, Silvio, et al.
Publicado: (2021)

Adaptive Designs: Lessons for Inflammatory Bowel Disease Trials
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Definition of mild to moderate ulcerative colitis in clinical trials: A systematic literature review
por: Caron, Bénédicte, et al.
Publicado: (2022)

Can we change the natural course of inflammatory bowel disease?
por: Le Berre, Catherine, et al.
Publicado: (2023)

Rediscovering histology: what is new in endoscopy for inflammatory bowel disease?
por: Solitano, Virginia, et al.
Publicado: (2021)

Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD)
por: Furfaro, Federica, et al.
Publicado: (2022)

Balancing Risks and Benefits in Inflammatory Bowel Disease Patients during the COVID-19 Pandemic
por: Kotze, Paulo Gustavo, et al.
Publicado: (2021)

Systematic Review on Inflammatory Bowel Disease Patients With Coronavirus Disease 2019: It Is Time to Take Stock
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Managing Inflammatory Bowel Disease During COVID-19: Summary of Recommendations from Gastrointestinal Societies
por: Hanzel, Jurij, et al.
Publicado: (2020)

Inflammatory Bowel Disease Management During the Coronavirus-19 Outbreak: A Survey From the European Crohn’s and Colitis Organization
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Patient and Public Involvement in Research: Lessons for Inflammatory Bowel Disease
por: Honap, Sailish, et al.
Publicado: (2023)

PDE4 Inhibition and Inflammatory Bowel Disease: A Novel Therapeutic Avenue
por: Spadaccini, Marco, et al.
Publicado: (2017)

Landscape of new drugs and targets in inflammatory bowel disease
por: Vieujean, Sophie, et al.
Publicado: (2022)

Early Intervention With Vedolizumab and Longer-term Surgery Rates in Crohn’s Disease: Post Hoc Analysis of the GEMINI Phase 3 and Long-term Safety Programmes
por: Dulai, Parambir S, et al.
Publicado: (2020)

Ultrasound Elastography in Inflammatory Bowel Diseases: A Systematic Review of Accuracy Compared with Histopathological Assessment
por: Dal Buono, Arianna, et al.
Publicado: (2022)

Pursuing neutrophils: systematic scoping review on blood-based biomarkers as predictors of treatment outcomes in inflammatory bowel disease
por: Magalhaes, Diogo, et al.
Publicado: (2023)

Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey
por: D'Amico, Ferdinando, et al.
Publicado: (2020)

Protecting patients with IBD during the COVID-19 pandemic
por: Fiorino, Gionata, et al.
Publicado: (2020)

Oral Iron for IBD Patients: Lessons Learned at Time of COVID-19 Pandemic
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2020)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Reply
por: D’Amico, Ferdinando, et al.
Publicado: (2021)

Ustekinumab in Crohn’s Disease: New Data for Positioning in Treatment Algorithm
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Ocular Manifestations in Patients with Inflammatory Bowel Disease in the Biologics Era
por: Cuny, Alix, et al.
Publicado: (2022)

Viral infections in inflammatory bowel disease: Tips and tricks for correct management
por: Craviotto, Vincenzo, et al.
Publicado: (2021)

Ulcerative colitis: Impact of early disease clearance on long‐term outcomes ‐ A multicenter cohort study
por: D’Amico, Ferdinando, et al.
Publicado: (2022)

Efficacy, Safety, and Concerns on Microbiota Modulation, Antibiotics, Probiotics, and Fecal Microbial Transplant for Inflammatory Bowel Disease and Other Gastrointestinal Conditions: Results from an International Survey
por: Parigi, Tommaso Lorenzo, et al.
Publicado: (2023)

Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus
por: D’Amico, Ferdinando, et al.
Publicado: (2023)

Intravenous Versus Oral Iron for the Treatment of Anemia in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
por: Bonovas, Stefanos, et al.
Publicado: (2016)

Tumour necrosis factor inhibitors in inflammatory bowel disease: the story continues
por: Peyrin-Biroulet, Laurent, et al.
Publicado: (2021)

Incidence and Patterns of COVID-19 Among Inflammatory Bowel Disease Patients From the Nancy and Milan Cohorts
por: Allocca, Mariangela, et al.
Publicado: (2020)

Inflammatory Bowel Disease Patients’ Acceptance for Switching from Intravenous Infliximab or Vedolizumab to Subcutaneous Formulation: The Nancy Experience
por: Remy, Clotilde, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ipghluubc1hq4bh35dgm1k9aba